Published in Surgery Litigation and Law Weekly, May 2nd, 2008
A Multidisciplinary Phase II Study of AZD2171 (cediranib), an Oral Pan-VEGF Receptor Tyrosine Kinase Inhibitor, in Patients with Recurrent Glioblastoma: Abstract LB-247
The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly